Neoadjuvant Chemotherapy Appears Effective in Patients with Mixed-Histology Bladder Cancer


May 3, 2010

Oncology Times

Naomi Haas, MD, an associate professor in the division of Hematology/Oncology and director of the Abramson Cancer Center's Prostate Program, is quoted in an Oncology Times story about new findings suggesting that locally advanced urothelial cancer patients whose tumors have squamous cell or adenocarcinoma elements derive at least as much benefit from platinum-based neoadjuvant chemotherapy as those individuals whose tumors are pure urothelial cancers. Haas called the findings, which were presented at a session she chaired at ASCO's 2010 Genitourinary Symposium, surprising. "It is counterintuitive," she said. "We generally are of the belief that transitional cell cancer benefits from platinum based therapy and that these mixed histology tumors, at least in advanced disease, don't do very well with these regimens. And here is a study saying, perhaps, that if you try to treat these patients earlier on, they may actually do better." Read More